Investor Presentaiton
Novo Nordisk Annual Report 2023
Introducing Novo Nordisk
Strategic Aspirations
Risks
Management
Consolidated statements
Additional information.
50
Income statement and Statement of comprehensive income
for the year ended 31 December
DKK million
Income statement
Net sales
Cost of goods sold
Gross profit
Note
2023
2022
2021
DKK million
Note
2023
2022
2021
2.1, 2.2 232,261
2.2 (35,765)
196,496
Sales and distribution costs
2.2
(56,743)
Research and development costs
2.2, 2.3
Administrative costs
2.2
(32,443)
(4,855)
Other operating income and expenses
2.2, 2.5
119
Operating profit
102,574
176,954 140,800
(28,448) (23,658)
148,506 117,142
(46,217) (37,008)
(24,047) (17,772)
(4,467)
1,034
74,809
Statement of comprehensive income
Net profit
83,683
55,525
47,757
Other comprehensive income:
Remeasurements of retirement benefit obligations
13
615
146
Items that will not be reclassified subsequently to the income statement
13
615
146
Exchange rate adjustments of investments in subsidiaries
4.3
(1,404)
2,289
1,624
(4,050)
Cash flow hedges:
332
Realisation of previously deferred (gains)/losses
4.3, 4.5
(1,026)
1,740
(1,802)
58,644
Deferred gains/(losses) incurred during the period
4.3, 4.5
1,612
1,026
(1,755)
Financial income
4.10
2,945
239
2,887
Other items
4.3
4
(3)
112
Financial expenses
4.10
(845)
Profit before income taxes
104,674
Income taxes
2.6
Net profit
Earnings per share
(20,991)
83,683
(5,986)
69,062
(13,537)
55,525
(2,451)
Income tax related to these items
2.6, 4.3
(359)
(889)
1,005
59,080
(11,323)
47,757
Items that will be reclassified subsequently to the income statement
(1,173)
4,163
(816)
Other comprehensive income
(1,160)
4,778
(670)
Total comprehensive income
82,523
60,303
47,087
Basic earnings per share (DKK)
4.1
18.67
12.26
10.40
Diluted earnings per share (DKK)
4.1
18.62
12.22
10.37View entire presentation